The Changing Therapeutic Landscape in Metastatic Prostate Cancer

Alan J Koletsky
Lynn Cancer Institute, Boca Raton, FL, US

DOI: https://doi.org/10.17925/OHR.2017.13.02.112

Over the past several years a number of novel and diverse agents have provided a significant clinical benefit for patients with metastatic castration-resistant prostate cancer including abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223. The early use of docetaxel or abiraterone at initiation of standard androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer has also led to substantial improvements in overall survival. The identification of a truncating mutation in the androgen receptor (AR-V7), a biomarker of resistance, may help clarify a more optimal sequencing of hormonal and chemotherapy-based therapies for patients with metastatic disease. The genomic landscape of both primary and metastatic prostate cancer has been an important focal point of translational research. The most widely studied pathways that affect tumorigenesis are the phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/protein kinase B (AKT) and poly ADP ribose polymerase (PARP) and DNA repair pathways. This review will highlight recent clinical trials which have had a major impact on the management of patients with metastatic disease with an emphasis on treatments driven by common genomic aberrations present in advanced prostate cancer.

Androgen ablation therapy (ADT) alone has long been the standard of care (SOC) for patients with metastatic prostate cancer initiating systemic therapy. Although most patients treated with standard ADT achieve a substantial prostate specific antigen (PSA) decline, transition to a castration-resistant state invariably occurs. In a large retrospective review of 659 patients with primary advanced prostate cancer and bone metastasis, the median duration of response to initial ADT was 22.4 months. Risk factors associated with a shorter overall survival (OS) in men treated with ADT alone included pre-treatment PSA level, Gleason score, and extent of bone involvement at diagnosis.

Chemo-hormonal therapy in metastatic hormone-sensitive prostate cancer—the CHAARTED and STAMPEDE trials

Early studies which sought to examine a potential efficacy of concurrent ADT and chemotherapy were limited by the small numbers of patients enrolled, many of whom had a low tumor burden at study entry. In the CHAARTED trial, 790 metastatic hormone-sensitive patients (mHSPC) were randomized to receive ADT alone or ADT plus docetaxel. Patients were prospectively stratified into high volume disease (defined as four or more bone metastases with at least one outside the vertebral column and pelvis and/or visceral metastases) and low-volume disease.

In the CHAARTED trial, 790 metastatic hormone-sensitive patients (mHSPC) were randomized to receive ADT alone or ADT plus docetaxel. Patients were prospectively stratified into high volume disease (defined as four or more bone metastases with at least one outside the vertebral column and pelvis and/or visceral metastases) and low-volume disease. Long-term results from the CHAARTED trial were presented at ESMO 2016. Patients receiving ADT plus docetaxel had a significant improvement in median OS compared with ADT alone (57.6 months versus 42 months; hazard ratio [HR] 0.73; p=0.0018). A subgroup analysis continued to show benefit from the addition of docetaxel only in the high volume group. The median OS in this group was 51.2 months for ADT plus docetaxel versus 34.4 months for ADT alone (HR 0.61; p<0.0001). Secondary end-points including time to clinical progression and quality of life (Functional Assessment of Cancer Therapy-Prostate [FACT-P] questionnaire) also benefited the group with high-volume disease. An OS benefit with earlier use of docetaxel and ADT in patients with low volume disease has yet to be demonstrated with longer follow-up; although, these patients had a longer time to onset of CRPC, PSA progression, and clinical progression.

The STAMPEDE trial included both non-metastatic (M0) and metastatic hormone-naive (M1) patients in two of the comparator arms each randomized to ADT plus chemotherapy (with or without zoledronic acid) and compared to a control group receiving ADT alone. A total of 592 men with newly diagnosed M1 disease were accrued to the ADT plus docetaxel arm of STAMPEDE. Docetaxel was started within 2 weeks of randomization, and approximately 9 weeks after initiation of ADT, similar to the time used...
in the CHAARTED trial. About 77% of patients in this cohort were able to complete all six planned cycles of docetaxel. The median OS benefit with the addition of docetaxel was approximately 10 months compared with ADT alone (81 versus 71 months). Patients who received chemotherapy had a 22% reduction in risk of all-cause death (HR 0.78). Pre-determined intermediate outcomes including prostate cancer specific survival benefit and failure-free survival (FFS) also favored the addition of docetaxel. The MD patient cohort had smaller numbers of enrolled patients with fewer deaths at last interim analysis and with an insufficient number of events to determine a potential benefit for docetaxel in this setting. Several other clinical trials have addressed the benefit of adding docetaxel to ADT for patients with hormone-sensitive high-risk non-metastatic or metastatic prostate cancer. Benefits have been seen for FFS but with contrasting results with regard to OS.

**Early use of abiraterone in metastatic hormone-sensitive prostate cancer—results from the LATTITUDE and STAMPEDE trials**

Abiraterone acetate (Zytiga®; Janssen, Beerse, Belgium) blocks the production of testicular, adrenal, and intra-tumor tissue/cell androgens resulting in a decrease in downstream androgen receptor (AR) signaling. Since AR signaling is necessary for androgen sensitive cell proliferation, it was postulated that abiraterone would have activity in earlier stages of the disease. A phase II trial of neoadjuvant abiraterone in combination with leuprolide and prednison e prior to radical prostatectomy, showed a pathologic complete response (CR), or near CR, in one-third of men with high-risk, localized prostate cancer.11

The results of two studies confirmed that early use of abiraterone significantly improves survival in men with metastatic hormone-sensitive prostate cancer. In the LATTITUDE phase III trial, 1,199 men with mHSPC were randomized to receive either ADT therapy plus abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily), or ADT plus dual placebo.12 Patients enrolled had at least two of the following three risk factors: Gleason score 8 or higher, three or more bone lesions, or measurable visceral metastases. The co-primary end points were OS and radiographic progression-free survival (rPFS). At the first interim analysis, after a median follow-up of 30.4 months, the median survival had not been reached in the abiraterone-treated group; the median OS in the control group was 34.7 months (HR 0.62; p<0.001). The 3 year OS for patients treated with abiraterone was 66% versus 49% in the placebo arm. The median duration of rPFS was 33.0 months in the abiraterone arm versus 14.8 months in the placebo arm (HR for disease progression = 0.47; p<0.001). Patients receiving abiraterone had higher rates of grade 3/4 adverse events (AEs) compared with the control arm. These included hypertension (20.3% versus 10.0%), hypokalemia (10.4% versus 1.3%), and elevated liver transaminases, alanine aminotransferase (ALT; 5.5% versus 1.3%), and aspartate aminotransferase (AST; 4.4% versus 1.5%).12

In the STAMPEDE trial, 1,917 patients with newly diagnosed locally advanced or high-risk mHSPC were randomized 1:1 to receive either abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily), plus standard of care (SOC) or SOC alone, defined as the administration of ADT therapy for 2 years or until disease progression. At time of study entry, 95% of patients were newly diagnosed; 52% had metastatic disease, and 88% had disease that had metastasized to bone. At a median follow-up of 40 months, 184 deaths had occurred in the abiraterone arm and 262 deaths in the SOC arm. The median-adjusted HR for median OS was 0.63 (p=0.0000012). Patients in the abiraterone arm also had a 55% reduction in time to development of skeletal-related events (SRE). AEs occurred more frequently in patients receiving abiraterone with 41% of patients experiencing grade 3/4 AEs versus 29% in the SOC control arm.

Both the LATTITUDE and STAMPEDE trials showed significant risk reductions for men with newly diagnosed hormone naïve high-risk metastatic prostate cancer treated with abiraterone. The survival benefits were quite similar with a 38% lower risk of death in the LATTITUDE and 37% lower relative risk of death in STAMPEDE. Early treatment with abiraterone is attractive for patients with metastatic prostate cancer initiating therapy who are not fit for chemotherapy. These patients tend to be older and often have multiple co-morbidities and poor bone marrow reserve. Some may simply choose not to receive chemotherapy.

The ARASENS trial (NCT02799602) is an ongoing international phase III double blind, placebo-controlled trial in which patients with newly diagnosed metastatic HSPC are randomized 1:1 to receive ODM-201, an oral AR antagonist or placebo both with standard ADT and docetaxel. The primary endpoint is OS.

**Immunotherapeutic approaches for the treatment of prostate cancer**

*Autologous vaccines—sipuleucel-T and the IMPACT trial*

Prostate cancer cells display a number of specific tumor-associated antigens, notably PSA, prostate acid phosphatase (PAP), and prostate-specific membrane antigen (PSMA), making them an attractive venue for immunotherapy. Autologous vaccines work by activating, priming, and enriching the host’s immune cells for reinfusion. Sipuleucel-T was the first vaccine approved for the treatment of cancer based on the results of the confirmatory IMPACT trial.14 Patients receiving sipuleucel-T had an improvement in OS of 4.1 months compared with the placebo arm and a 22% reduction in the risk of death. The survival benefit was maintained in pre-specified subgroups that included Eastern Cooperative Oncology Group (ECOG) performance status 0 versus 1, Gleason score (<7 or >8), PSA level above or below median, and number of bone metastases (0–5, 6–10, >10). Currently there are no surrogate biomarkers for response to this vaccine or endpoints for survival. The optimal selection of patients who benefit the most from sipuleucel-T in IMPACT has been retrospectively reviewed by Schellhammer, et al.15 The most important prognostic factor was baseline PSA. PSA levels were divided into quartiles to assess the predictive value at each quartile on OS. While all PSA quartile groups benefitted from sipuleucel-T, patients in the lowest baseline quartile (PSA <22) had the most benefit with an estimated improvement in median survival of 13 months compared with 2.8 months in the highest quartile group (PSA >134). This supports the earlier use of sipuleucel-T in patients with metastatic disease.

*Viral-vector-based vaccines—PROSTVAC-VF*

PROSTVAC-VF is a poxvirus-based vaccine in which PSA is bound to TRICOM. The vaccine is injected subcutaneously and the complex is taken up by dendritic cells that activate anti-PSA T cells which target prostate cancer cells displaying membrane-bound PSA. The lysed cancer cells release new tumor-associated antigens which activate more T cells thereby expanding the anti-tumor effect. In an early phase II study with PROSTVAC-VF, 125 patients with minimally symptomatic mCRPC were randomized to receive the vaccine or placebo.20
The primary endpoint of this study was PFS. Although this end point was not met, OS after 3 years of follow-up was increased significantly in the PROSTAC-VF treated arm by 8.5 months (25.1 versus 16.6 months: HR 0.56; p=0.0061). In a subsequent phase II study, PROSTAC-VF increased PFS by more than 6 months in 63% of patients. There was also a significant slowing of the PSA doubling time from 5.3 months to 7.7 months. The PROSPECT Global Phase III trial (NCT01322490) randomized men with non-symptomatic or minimally symptomatic mCRPC to one of three arms: PROSTAC-VF + adjuvant granulocyte-macrophage colony stimulating factor (GM-CSF) (arm 1); PROSTAC-VF + adjuvant placebo (arm 2), or vector placebo (adjuvant placebo) (arm 3). No cross over was allowed and patients went on to receive SOC treatment following progression. PROSPECT has completed accrual and results from this trial are expected shortly.

**Immune checkpoint inhibition in metastatic castration-resistant prostate cancer**

Prostate cancers have a low mutation rate and limited CD8-T cell infiltration and rarely express programmed death 1 (PD-1), unlike bladder and renal cell cancers where PD-1/programmed death-ligand 1 (PD-L1) therapy is effective. A phase Ib trial of nivolumab in 17 patients with advanced prostate cancer failed to show any objective responses. Bishop et al. have demonstrated that non AR-mediated upregulation of PD-L1 expression occurs in both enzalutamide-resistant pre-clinical models and patients with prostate cancer. In a recent phase II trial, patients who had progressed on enzalutamide were treated with the anti-PD-1 antibody pembrolizumab. Three of the first 10 patients treated had rapid and significant decreases in PSA from pre-treatment levels of 46, 71, and 2,503 to <0.1. Two of the three patients with measurable disease (one with liver metastases) had a partial response and two were able to discontinue opiate analgesics. All three patients remained free of progression at 30, 55, and 16 weeks of follow-up. Two of the three responders had a baseline biopsy prior to starting pembrolizumab. Biopsies from these patients showed presence of CD8 tumor infiltration and PD-L1 expression. Of the remaining seven patients, three had stable disease at 30, 47, and 50 weeks, which were ongoing, and four patients had disease progression. Expected immune-related AEs were observed. None of the responders had an immune-related AE. A phase III trial in men with locally advanced or mCRPC, comparing the anti-PD-L1 antibody, atezolizumab plus enzalutamide with enzalutamide alone, is currently in progress (NCT03016312).

**Combination immunotherapy strategies**

Despite the lack of efficacy of anti-PD-1/PD-L1 antibody monotherapy in the treatment of mCRPC, there is a renewed interest in exploring combination checkpoint inhibitors which can work synergistically to restore cellular-mediated antitumor immunity. The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1 pathways that inhibit both T-cell activation and mediated antitumor immunity. The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1 pathways that inhibit both T-cell activation and survival. In prostate cancer, however, the PI3k pathway is significantly de-regulated. Aberrant PI3k/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling is present in ~90% of men with advanced prostate cancer, and loss of phosphatase and tensin homolog (PTEN) leads to activation of the phosphatase and tensin homolog (PTEN) pathway and PTEN loss in prostate cancer. PTEN loss indicates resistance to ADT, disease progression, and poor outcomes in men with prostate cancer. The development and clinical utility of agents that block the interaction between AR signaling and PTEN pathways, with the goal of overcoming treatment resistance in men with PTEN-loss and the identification of biomarkers that can predict response to PI3k pathway inhibitors, are areas of active interest.

de Bono et al. have presented a study supporting PTEN loss as a prognostic marker for response to treatment with ipatasertib, a potent oral competitive

**Androgen receptor signaling and the PI3k pathway and PTEN loss in prostate cancer**

AR signaling occurs throughout the course of prostate cancer and drives cell growth and survival in early and late stages of the disease. Despite initial responses to ADT, resistance to treatment inevitably occurs due to AR reactivation and signaling, despite castrate levels of testosterone. AR gene amplification and overexpression, increased sensitivity to agonists, and ligand-independent AR reactivation mediated by AR splice variants also occurs in prostate cancer. The PI3k pathway is significantly de-regulated. Aberrant PI3k/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling is present in ~90% of men with advanced prostate cancer, and loss of phosphatase and tensin homolog (PTEN) leads to activation of the phosphatase and tensin homolog (PTEN) pathway and PTEN loss in prostate cancer. PTEN pathway activation is associated with resistance to ADT, disease progression, and poor outcomes in men with prostate cancer. The development and clinical utility of agents that block the interaction between AR signaling and PTEN pathways, with the goal of overcoming treatment resistance in men with PTEN-loss and the identification of biomarkers that can predict response to PI3k pathway inhibitors, are areas of active interest.
inhibitor of PI3k- AKT signaling. Patients with mCRPC, previously treated with docetaxel, were randomized to ipatasertib at a dose of 400 mg, 200 mg, or placebo in combination with abiraterone 1,000 mg and prednisone 10 mg, orally, daily. PTEN expression was assessed by IHC and PTEN-loss by fluorescent in situ hybridization (FISH) and next generation sequencing (NGS). PTEN IHC was evaluated in 165 of the 253 patients randomized, and of these, PTEN loss was detected in 71 (41%). Median rPFS was 7.5 months in the PTEN-loss ipatasertib plus abiraterone arm, and 5.6 months in the non-PTEN abiraterone plus placebo arm. In the PTEN-loss arm the rPFS survival benefit was greatest at the 400 mg dose of ipatasertib. Based on these results, the combination of ipatasertib and abiraterone is further being explored in a phase III trial (IPATential150; NCT03072238).

Treatment of patients with DNA repair alterations—the TOPARP-A trial

Genomic alterations that inactivate genes involved in the repair of DNA damage through homologous recombination (PARP), are present in approximately 22.7% of men with prostate cancer. Men with metastatic prostate cancer and gene mutations such as PARP have sustained responses to PARP inhibitors and platinum-based chemotherapy (Figure 1).

In the pivotal TOPARP-A trial, 50 men with previously-treated mCRPC, received the oral PARP inhibitor, olaparib, at a dose of 400 mg twice daily until radiographic progression, clinical progression, or development of serious AEs. The primary endpoint was overall response rate (ORR) defined as either objective response, PSA decrease of >50%, or reduction in the number of circulating tumor cells. Tumor biopsies from all patients were submitted for NGS, exome transcriptome analysis, and digital polymerase chain reaction testing. Several actionable mutations that relate to DNA repair pathways were identified including BRCA1, BRCA2, ATM, CHEK2, and FANCONI anemia genes (FANCA). One or more of these mutations was present in 16 patients (33%). BRCA2 mutations were present in seven patients (four with bi-allelic somatic loss, three with germline mutations), ATM mutations in five patients, homozygous somatic deletions of BRCA1 or CHEK2 with FANCA deletion in three patients, a somatic frameshift mutation in PALB2 (a localizer of BRCA2) in one patient with a heterozygous PALB2 deletion, and a bi-allelic somatic mutation in HDAC (which plays a role in ATM function) in one patient. Responses were seen in 14 of 16 patients (88%) with DNA-repair gene mutations, compared with two of 33 patients (6%) without these mutations (p<0.001). Median rPFS was longer in mutation-positive patients with DNA-repair defects treated with olaparib than in the mutation-negative group (9.8 versus 2.7 months; p<0.001) as was OS (13.8 versus 7.5 months; p<0.05). The most common grade >3 AEs were anemia (20%), fatigue (12%), and leukopenia (6%). Dose reduction of olaparib to 300 mg twice daily was required in 26% of patients, most commonly due to anemia. AEs led to treatment discontinuation in 6% of patients. Based on these clinically significant results, olaparib received breakthrough designation by the US Food and Drug Administration (FDA) for the treatment of BRCA1/2 or ATM gene-mutated mCRPC in January 2016.

Several other PARP inhibitor trials involving deleterious homologous recombination DNA repair (HRR) aberrations, are planned or in progress. The PROfound trial (NCT02987543) is a randomized, phase III trial that is evaluating olaparib’s efficacy and safety versus physician’s choice of either abiraterone or enzalutamide. Cohort A includes patients with mCRPC and BRCA 1, BRCA2, or ATM mutations, while cohort B will include patients with 12 other HRR genes. Patients will be randomized (2:1) to olaparib 300 mg orally twice daily to the standard treatment arm. Treatment will be continued until radiographic progression or lack of treatment tolerability. The primary end-point is rPFS. Secondary end-points include confirmed ORR, time to pain progression, OS (all Cohort A and rPFS (both cohorts combined), Rucaparib is an oral small molecule inhibitor of PARP that was recently approved as monotherapy for patients with BRCA2 mutation-positive advanced ovarian cancer following chemotherapy. The phase II TRITON2 trial (NCT02952534) will determine the response rate with rucaparib treatment in patients with mCRPC associated with BRCA1/2 or ATM mutations, who have progressed on both AR-targeted therapy and taxane-based chemotherapy. TRITON3 (NCT029759934) has a similar trial design to PROfound except that patients will be screened for BRCA1/2 or ATM mutations only, and subsequently randomized to receive rucaparib or abiraterone, enzalutamide or docetaxel chemotherapy, as recommended by the treating physician.

Summary

Prostate cancer is the most common cancer afflicting men in North America and is estimated to become the third leading cause of death behind lung cancer and colorectal cancers. Although prostate cancers are clinically heterogeneous, AR signaling occurs in all stages of the disease and suppression of the AR remains the cornerstone of therapy. The early addition of chemotherapy (docetaxel) or hormone therapy (abiraterone) to standard ADT for patients with newly diagnosed hormone-sensitive metastatic disease, has resulted in a robust improvement in OS. Immunotherapeutic strategies that utilize different checkpoint inhibitors to both stimulate T-cell activation and inhibit downstream immune-modulating resistance pathways have shown clinical benefit in other solid tumor types and results from current and future clinical trials in prostate cancer are eagerly awaited to determine whether such synergy will provide additional clinical benefit.

Continued progress in transcriptional and genomic profiling has led to the identification of a number of clinically actionable mutations that are common in men with mCRPC, thereby affording new avenues of personalized therapy.
Review Prostate Cancer

for mutation-positive patients. In particular, genomic alterations of the PI3K-AKT/mTOR signaling pathway and its interaction with AR signaling and PTEN, have led to the development of novel agents that target different kinases in this pathway and show early promise in clinical trials. Both somatic and germline aberrations in DNA repair genes can restore sensitivity to PARP inhibition, and show significant activity in men with BRCA2, BRCA1, and ATM mutations. Comparison with standard therapies used in the initial treatment of mCRPC will be needed to determine whether PI3K-AKT signaling inhibitors, and PARP inhibitors, can be utilized in the frontline setting. The analysis of genomic profiling of tumor specimens in patients with metastatic prostate cancer can be challenging at times due to lack of sufficient viable tissue particularly from sites of bone metastasis. Further refinements of liquid biopsies which analyze circulating tumor cells, and cell-free DNA may provide an attractive alternative methodology. With the anticipated identification of additional genomic aberrations that drive prostate cancer cell growth and proliferation and the potential to identify new targeted therapies or uncover new mechanisms of resistance to available agents, the therapeutic landscape in advanced prostate cancer is more diverse than ever.